DOCSLIB.ORG

Use Patterns and Self-Reported Effects of Salvia Divinorum: an Internet-Based Survey

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Use Patterns and Self-Reported Effects of Salvia Divinorum: an Internet-Based Survey Drug and Alcohol Dependence 111 (2010) 250–256 Contents lists available at ScienceDirect Drug and Alcohol Dependence journal homepage: www.elsevier.com/locate/drugalcdep Use patterns and self-reported effects of Salvia divinorum: An internet-based survey Matthew J. Baggott a,b,∗, Earth Erowid c, Fire Erowid c, Gantt P. Galloway b, John Mendelson b a Helen Wills Neuroscience Institute, University of California - Berkeley, Berkeley, CA, USA b Addiction and Pharmacology Research Laboratory, California Pacific Medicial Center Research Institute, San Francisco, CA, USA c Erowid Center, Grass Valley, CA, USA article info abstract Article history: Background: There is growing use of Salvia divinorum (SD), a psychoactive plant that produces Received 30 October 2009 hallucinogen-like effects through a kappa opioid receptor (KOR) mechanism. Little is known about KOR Received in revised form 4 May 2010 agonist effects in humans and about users of SD. Accepted 6 May 2010 Objectives: To characterize the reasons, methods, and reported consequences of SD use. Methods: Individuals reading SD-related pages of a drug-information website were invited to anony- mously complete an online questionnaire if they had used SD. Keywords: Results: Participants (N = 500) were 92.6% male and 23.4 ± 8.7 (mean ± s.d.) years old. They had used a Salvia divinorum Hallucinogen median of six times (range 1–250). 80.6% probably or definitely would use SD again. Most participants Kappa opioid (92.6%) typically smoked or vaporized SD product. When smoked, the drug’s main effects were estimated Patterns of use to last 14.1 ± 12.8 (range 0.5–120) minutes. When asked to compare SD effects to other methods of alter- Subjective effects ing consciousness, the most common answer was that SD was unique (38.4%). 25.8% reported persisting (≥24 h) positive effects (often described as increased sense of well-being) on at least one occasion. 4.4% reported persisting negative effects (most often anxiety). Conclusions: SD is typically smoked, acute effects are brief, and persistent adverse effects are uncommon. In addition to acute hallucinogenic effects, SD may produce subacute increases in subjective well-being. Such a subacute effect would be unusual for a drug that is used non-medically, as withdrawal from other drugs typically either does not affect mood or causes dysphoria. Findings from this convenience sample should be confirmed and extended using surveys of random samples and controlled clinical studies. © 2010 Elsevier Ireland Ltd. All rights reserved. 1. Introduction et al., 2005; Kovacs et al., 2005; Mitchell et al., 2005; Zapata and Shippenberg, 2006). Variations in the genes encoding the KOR and Pharmacological manipulations of the kappa opioid recep- two ligands have been associated with a risk for alcohol dependence tor (KOR) system have been proposed as novel treatments for (Xuei et al., 2006). In addition, a KOR agonist reduces convul- depression and drug and alcohol dependence (Carroll et al., 2005; sion severity in animals susceptible to ethanol withdrawal seizures Gaveriaux-Ruff and Kieffer, 2002; Kieffer and Gaveriaux-Ruff, (Beadles-Bohling and Wiren, 2006). 2002). KOR antagonists show antidepressant-like effects and atten- Despite this acknowledged therapeutic potential, few clinical uate behavioral responses to stress (Mague et al., 2003), while KOR studies have employed KOR agonists and little is known about their stimulation modulates the reward system by reducing dopamine effects in humans. One apparent reason is that, at high doses, KOR release in the nucleus accumbens, and by generating aversive states agonists such as cyclazocine, enadoline, and spiradoline produce (Aldrich and Vigil-Cruz, 2003; Spanagel et al., 1990). KOR manip- sensory effects such as visual and auditory distortions and feel- ulations modulate ethanol consumption in rodents, and ethanol- ings of depersonalization (Chappell et al., 1993; Martin et al., 1965; and cocaine-induced alteration in brain dopamine levels (Chefer Pfeiffer et al., 1986; Walsh et al., 2001). At lower doses, KOR ago- nists also produce decreased body temperature, diuresis, sedation, stupor, and difficulty concentrating (Ashton et al., 1989; Chappell et al., 1993; Kramer et al., 2000; Martin et al., 1965; Pfeiffer et al., ∗ Corresponding author at: Addiction and Pharmacology Research Laboratory, 1986; Reece et al., 1994; Rimoy et al., 1994; Walsh et al., 2001). California Pacific Medical Center Research Institute, 7th Floor, St Luke’s Hospital, Cardiovascular effects from kappa agonists are reportedly minimal 3555 Cesar Chavez Street, San Francisco, CA 94110, USA. Tel.: +1 415 641 3370; fax: +1 415 641 3380. (Rimoy et al., 1994; Walsh et al., 2001). Selective KOR antagonists E-mail address: [email protected] (M.J. Baggott). are not available for use in clinical trials at present. 0376-8716/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.drugalcdep.2010.05.003 M.J. Baggott et al. / Drug and Alcohol Dependence 111 (2010) 250–256 251 Salvia divinorum (SD) is a hallucinogenic plant that has been Table 1 traditionally used for divination and healing in the Mazatec zone of Estimated duration of Salvia divinorium effects when smoked or vaporized. Mexico (Johnson, 1939), and was first collected by Westerners in Estimated duration of effects when smoked or vaporized (min) 1955 (Epling and Jativa, 1962). In the United States, a 2008 gov- SD extract (N = 296) SD leaf (N = 180) Salvinorin A (N =6) ernment report estimated that 1.8 million people had tried SD, with most initiating use in the last two years (Substance Abuse Mean 14.1 15.7 27.5 St. Dev. 12.8 14.8 16.1 and Mental Health Services Administration, 2008). SD use has been Median 10 10 21 reported in college students in the United States (Khey et al., 2008; Mode 10 5 N/A Lange et al., 2008) and is also occurring in Europe (Pavarin, 2006) Min 0 0 13 and Japan (Tsujikawa et al., 2008). At least in a sample of Italian Max 120 90 50 youth attending concerts, SD users appear to have fewer medical, legal, or social impairments than do individuals who consume other found any of the survey questions difficult to understand, and whether they had recreational drugs (Pavarin, 2006). previously completed this survey. The putative primary psychoactive agent in SD is a structurally When participants finished the survey, they clicked a button on the bottom novel KOR agonist named salvinorin A (Ortega et al., 1982; Valdés et of the page affirming that their responses were complete. Their responses were al., 1984). Consistent with KOR agonist activity, users describe SD in then anonymously stored in an electronic database. If participants did not click this button, none of their responses were stored. The automatically collected web-server lay literature as hallucinogenic: it produces perceptual distortions, activity log counted the number of times the announcement was read, the number pseudo-hallucinations, and a profoundly altered sense of self and of times the information sheet was read, and the number of times the survey was environment, including out-of-body experiences (Aardvark, 1998; completed. Erowid, 2008; Siebert, 1994b; Turner, 1996). SD therefore appears Data from a participant were excluded from analysis if: (1) data were incom- to have the potential to elucidate the role of the KOR receptor sys- plete; (2) the participant reported having previously completed the survey; (3) the participant reported he or she was not fluent in English or had difficulty understand- tem in health and disease (Butelman et al., 2004; Chavkin et al., ing the questions; or (4) another response was submitted from the same computer 2004; Roth et al., 2002). (IP address) within ten minutes. The survey ended when 500 participants completed Aside from books and web sites providing information to poten- the survey and met inclusion and exclusion criteria. tial users (Aardvark, 1998; Erowid, 2008; Ott, 1993; Pendell, 1995; Data were analyzed using R (R Development Core Team, 2007). Siebert, 2009; Sociedad, 1998; Turner, 1996), there is very lit- tle published information on users’ experiences with the drug 3. Results (Gonzalez et al., 2006; Lange et al., 2009). For that reason, study- ing SD users appears to be a novel method for understanding the We collected a total of 520 responses (40.1% of those viewing the effects of high and repeated exposure to a KOR agonist in humans. survey), of which 500 met inclusion/exclusion criteria. Participants We therefore conducted an anonymous web-based survey of SD were primarily (92.6%) male. The mean age was 23.4 ± 8.7 years use. Participants were asked to report basic demographic and drug- (range 13–68), with 20.2% under 18 years of age. 77.4% lived in the effect information as well has when, how, and why they had used United States. SD. 3.1. Usage patterns 2. Methods Participants reported a mean (±standard deviation) lifetime use We recruited anonymous participants from a popular drug-information web site ± that does not take a position against drug use (www.erowid.org). Individuals visiting of SD products to be 13.3 22.9 (median 6; range 1–250) days the web site’s pages relating to SD saw an announcement about the questionnaire, (Fig. 1). The number of days SD was used in the last 30 and 365 which appeared as a hyperlink reading, “Survey for people who have used Salvia days was 1.5 ± 2.6 (median 1; range 0–24) and 7.5 ± 11.6 (median divinorum”. Prospective participants who clicked on this link then read an informa- 3; range 0–110), respectively. Most individuals (92.6%) typically tion sheet describing the study and its potential risks. Prospective participants from Australia were asked not to participate due to legal restrictions on SD in that country. smoked or vaporized the SD products, with 61.4% of this subset Participants went on to fill out a 39-item survey, requiring approximately 20 min.
Load more

Recommended publications
  • Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
    REVIEW ARTICLE published: 01 February 2013 doi: 10.3389/fphar.2013.00007 Drug development for the irritable bowel syndrome: current challenges and future perspectives Fabrizio De Ponti* Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Edited by: Medications are frequently used for the treatment of patients with the irritable bowel syn- Angelo A. Izzo, University of Naples drome (IBS), although their actual benefit is often debated. In fact, the recent progress in Federico II, Italy our understanding of the pathophysiology of IBS, accompanied by a large number of preclin- Reviewed by: Elisabetta Barocelli, University of ical and clinical studies of new drugs, has not been matched by a significant improvement Parma, Italy of the armamentarium of medications available to treat IBS. The aim of this review is to Raffaele Capasso, University of outline the current challenges in drug development for IBS, taking advantage of what we Naples Federico II, Italy have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions *Correspondence: that will be addressed are: (a) do we still believe in the “magic bullet,” i.e., a very selective Fabrizio De Ponti, Pharmacology Unit, Department of Medical and Surgical drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS Sciences, University of Bologna, Via is a “functional disorder” where complex neuroimmune and brain-gut interactions occur Irnerio, 48, 40126 Bologna, Italy. and minimal inflammation is often documented:
    [Show full text]
  • CSAS Narcotic Treatment Service for Opiate Addiction Initial Certification
    DEPARTMENT OF HEALTH SERVICES STATE OF WISCONSIN Division of Quality Assurance Page 1 of 16 F-00538 (11/11) COMMUNITY SUBSTANCE ABUSE SERVICE (CSAS) NARCOTIC TREATMENT SERVICE FOR OPIATE ADDICTION INITIAL CERTIFICATION APPLICATION Chapter DHS 75.15 Initial Certification • Initial certification must meet all requirements, including staffing requirements (hired and in place) before services begin. • This document paraphrases the rule language for application purposes. • Applicants for a new narcotic treatment service for opiate addiction must demonstrate preparedness to comply with all Chapter DHS 75.15 standards. Applicants will have completed all required policies, including Chapter DHS 94 (Patient Rights). Use the check boxes ( ) to affirm readiness to meet standards. • ATTENTION: The clinic must contact the regional Health Services Specialist to arrange a site visit following the submission of fee and this application. Chapter DHS 75.01(1) Authority and Purpose This application is promulgated under the authority of ss. 46.973(2)(c), 51.42(7)(b), and 51.45(8) and (9), Wis. Stats., to establish standards for community substance abuse prevention and treatment services under ss. 51.42 and 51.45, Wis. Stats. Sections 51.42(1) and 51.45(1) and (7) provide that a full continuum of substance abuse services be available to Wisconsin citizens from county departments of community programs, either directly or through written agreements or contracts that document the availability of services. This application provides that service recommendations for initial placement, continued stay, level of care transfer, and discharge of a patient be made through the use of Wisconsin uniform placement criteria (WI- UPC), American Society of Addiction Medicine (ASAM) placement criteria, or similar placement criteria that may be approved by the department.
    [Show full text]
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • Peripheral Kappa Opioid Receptor Activation Drives Cold Hypersensitivity in Mice
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.04.325118; this version posted October 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice Manish K. Madasu1,2,3, Loc V. Thang1,2,3, Priyanka Chilukuri1,3, Sree Palanisamy1,2, Joel S. Arackal1,2, Tayler D. Sheahan3,4, Audra M. Foshage3, Richard A. Houghten6, Jay P. McLaughlin5.6, Jordan G. McCall1,2,3, Ream Al-Hasani1,2,3 1Center for Clinical Pharmacology, St. Louis College of Pharmacy and Washington University School of Medicine, St. Louis, MO, USA. 2Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, MO, USA 3Department of Anesthesiology, Pain Center, Washington University. St. Louis, MO, USA. 4 Division of Biology and Biomedical Science, Washington University in St. Louis, MO, USA 5Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA 6Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL, USA Corresponding Author: Dr. Ream Al-Hasani Center for Clinical Pharmacology St. Louis College of Pharmacy Washington University School of Medicine 660 South Euclid Campus Box 8054 St. Louis MO, 63110 [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.10.04.325118; this version posted October 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Curriculum Vitae: Lin Chang
    CURRICULUM VITAE LIN CHANG, M.D. Professor of Medicine Vatche and Tamar Manoukian Division of Digestive Diseases David Geffen School of Medicine at UCLA PERSONAL HISTORY: Office Address: G. Oppenheimer Center for Neurobiology of Stress and Resilience 10833 Le Conte Avenue CHS 42-210 Los Angeles, CA 90095-7378 (310) 206-0192; FAX (310) 825-1919 EDUCATION: 1978 - 1982 University of California, Los Angeles, Degree: B.S. Biochemistry 1982 - 1986 UCLA School of Medicine, Los Angeles, Degree: M.D. 1986 - 1987 Internship: Harbor-UCLA Medical Center, Internal Medicine 1987 - 1989 Residency: Harbor-UCLA Medical Center, Internal Medicine 1989 - 1990 Research Fellowship: Harbor-UCLA Medical Center, Division of Gastroenterology 1990 - 1992 Clinical Fellowship: UCLA Integrated Program, Gastroenterology BOARD CERTIFICATION: ABIM: Internal Medicine 1989 Gastroenterology 1993, recertification 2014 PROFESSIONAL EXPERIENCE: 2006- present Professor of Medicine-in-Residence, Division of Digestive Diseases, David Geffen School of Medicine at UCLA 2000 - 2006 Associate Professor of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at UCLA 1997 - 2000 Assistant Professor of Medicine, Division of Digestive Diseases, UCLA School of Medicine Chang 2 1993 - 1997 Assistant Professor of Medicine-in-Residence, UCLA, Harbor-UCLA Medical Center 1992 - 1993 Associate Consultant, Mayo Clinic, Rochester, Minnesota, Department of Gastroenterology PROFESSIONAL ACTIVITIES: 2017 – present Vice-Chief, Vatche and Tamar Manoukian Division of Digestive
    [Show full text]
  • Preventing Alcohol and Other Drug Use in Student-Athletes
    Preventing Alcohol and Other Drug Use in Student-Athletes Most Student-Athletes Alcohol Use Don’t Use/Misuse Most don’t misuse alcohol. See percentages of higher risk drinking within the last 12 months.* % of student-athletes reporting “never used” PERCENTAGES OF ALCOHOL USE EFFECTS ON ATHLETIC PERFORMANCE BASED ON AMOUNT 99.6% Heroin • Constricts aerobic metabolism and endurance 99.5% Methamphetamine Division I Division II Division III • Requires increased work to maintain 1.0% 1.6% 1.8% weight 99.1% Anabolic steroids Female • Inhibits absorption of nutrients, More than which then: 98.2% Ultracet, Ultram or Tramadol 4 drinks 38.9% 33.1% 41.2% - Reduces endurance 98.0% Amphetamines 10+ drinks - Decreases protein synthesis for muscle fiber repair 97.4% Human growth hormone (HGH) - Decreases immune response 97.3% Injectable Toradol - Increases risk of injury Male 10.7% 11.5% 15.8% • Alcohol use 24 hours before athletic 97.1% LSD More than activity significantly reduces aerobic 5 drinks 39.0% 38.6% 51.8% performance 96.1% Ecstacy/Molly 10+ drinks • Weekly alcohol consumption 94.5% Cocaine doubles the rate of injury 84.5% ADHD stimulants WITHIN THE 18.2% say they did not drink EFFECTS OF A HANGOVER 83.3% Narcotic pain medication within the last year LAST YEAR, • Increases heart rate HAVE YOU 75.3 % Marijuana • Decreases left ventricular performance EXPERIENCED A • Increases blood pressure 49.0% Tylenol or acetaminophen HANGOVER AS • Decreases endurance performance A CONSEQUENCE • Dehydration 44.6% NSAIDs OF DRINKING ALCOHOL? No: Yes: 19.8% Alcohol 29.8% 52% Marijuana Use Stimulant Use Narcotic Use Most don’t use marijuana.
    [Show full text]
  • The Opioid Epidemic: What Labs Have to Do with It?
    The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 1 Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 2 Analysis. Answers. Action. www.aphl.org Opiates and Opioids • Opiates vs. Opioids • Opiates: Naturally occurring, derived from the poppy plant • Opioids: “Opiate-like” drugs in effects, not chemical structure Includes opiates • Narcotic analgesics • CNS depressants • DEA Schedule I or II controlled substances • Additive effect with other CNS depressant drugs Analysis. Answers. Action. www.aphl.org Efficacy of Opioids • How do opioids work? • Bind with opioid receptors • Brain, spinal cord, GI tract, and throughout the body • Pain, emotion, breathing, movement, and digestion Opioid Receptor Analysis. Answers. Action. www.aphl.org Effects of Opioids Physiological Psychological • Pain relief • Drowsiness/ sedation • Cough suppression • Mental confusion • GI motility • Loss of memory • Respiratory depression • Lethargy/ apathy • Pupillary constriction • Euphoria/ tranquility • Itching • Mood swings • Constipation • Depression • Dependence • Withdrawal • Dependence Analysis. Answers. Action. www.aphl.org Opiates 1 Opiates • Naturally occurring alkaloids Opium • Latex from the opium poppy plant Codeine: • Mild to moderate pain • Antitussive Morphine: • Severe pain • Metabolite of codeine and heroin Analysis. Answers. Action. www.aphl.org Opiates 2 Semi-synthetic Opiates: • Synthesized from a natural opiate Heroin: • Schedule I narcotic Hydrocodone (Vicodin): • Mild to moderate pain • Metabolizes to hydromorphone (Dilaudid) Oxycodone (Oxycontin/Percocet): • Moderate to severe pain • Metabolizes to oxymorphone (Opana) Analysis. Answers. Action.
    [Show full text]
  • Euphoric Non-Fentanil Novel Synthetic Opioids on the Illicit Drugs Market
    Forensic Toxicology (2019) 37:1–16 https://doi.org/10.1007/s11419-018-0454-5 REVIEW ARTICLE The search for the “next” euphoric non‑fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Kirti Kumari Sharma1,2 · Tim G. Hales3 · Vaidya Jayathirtha Rao1,2 · Niamh NicDaeid4,5 · Craig McKenzie4 Received: 7 August 2018 / Accepted: 11 November 2018 / Published online: 28 November 2018 © The Author(s) 2018 Abstract Purpose A detailed review on the chemistry and pharmacology of non-fentanil novel synthetic opioid receptor agonists, particularly N-substituted benzamides and acetamides (known colloquially as U-drugs) and 4-aminocyclohexanols, developed at the Upjohn Company in the 1970s and 1980s is presented. Method Peer-reviewed literature, patents, professional literature, data from international early warning systems and drug user fora discussion threads have been used to track their emergence as substances of abuse. Results In terms of impact on drug markets, prevalence and harm, the most signifcant compound of this class to date has been U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), reported by users to give short- lasting euphoric efects and a desire to re-dose. Since U-47700 was internationally controlled in 2017, a range of related compounds with similar chemical structures, adapted from the original patented compounds, have appeared on the illicit drugs market. Interest in a structurally unrelated opioid developed by the Upjohn Company and now known as BDPC/bromadol appears to be increasing and should be closely monitored. Conclusions International early warning systems are an essential part of tracking emerging psychoactive substances and allow responsive action to be taken to facilitate the gathering of relevant data for detailed risk assessments.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20100227876A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0227876 A1 Rech (43) Pub. Date: Sep. 9, 2010 (54) METHODS OF REDUCING SIDE EFFECTS Publication Classi?cation OF ANALGESICS (51) Int CL A61K 31/485 (2006.01) A61K 31/40 (2006.01) (75) Inventor: Richard H. Rech, Okemos, MI A61K 31/445 (2006-01) (Us) A61K 31/439 (2006.01) (52) US. Cl. ........................ .. 514/282; 514/409; 514/329 (57) ABSTRACT Correspondence Address: The invention provides for compositions and methods of MARSHALL, GERSTEIN & BORUN LLP reducing pain in a subject by administering a combination of 233 SOUTH WACKER DRIVE, 6300 WILLIS mu-opioid receptor agonist, kappal-opioid receptor agonist TOWER and a nonselective opioid receptor antagonist in amounts CHICAGO, IL 60606-6357 (US) effective to reduce pain and ameliorate an adverse side effect of treatment combining opioid-receptor agonists. The inven tion also provides for methods of enhancing an analgesic effect of treatment With an opioid-receptor agonist in a sub (73) Assignee: RECHFENSEN LLP, RidgeWood, ject suffering from pain While reducing an adverse side effect NJ (US) of the treatment. The invention also provides for methods of reducing the hyperalgesic effect of treatment With an opioid receptor agonist in a subject suffering from pain While reduc ing an adverse side effect of the treatment. The invention (21) Appl. No.: 12/399,629 further provides for methods of promoting the additive anal gesia of pain treatment With an opioid-receptor agonist in a subject in need While reducing an adverse side effect of the (22) Filed: Mar.
    [Show full text]
  • Hallucinogens
    Hallucinogens What Are Hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and others are synthetic (human-made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes. Hallucinogens are a Types of Hallucinogens diverse group of drugs Classic Hallucinogens that alter perception, LSD (D-lysergic acid diethylamide) is one of the most powerful mind- thoughts, and feelings. altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other Hallucinogens are split grains. into two categories: Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) comes from certain classic hallucinogens and types of mushrooms found in tropical and subtropical regions of South dissociative drugs. America, Mexico, and the United States. Peyote (mescaline) is a small, spineless cactus with mescaline as its main People use hallucinogens ingredient. Peyote can also be synthetic. in a wide variety of ways DMT (N,N-dimethyltryptamine) is a powerful chemical found naturally in some Amazonian plants. People can also make DMT in a lab.
    [Show full text]
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • (Methadone Hydrochloride Oral Concentrate USP) and Methadose
    NDA 17-116/S-021 Page 3 Methadose™ Oral Concentrate (methadone hydrochloride oral concentrate USP) and Methadose™ Sugar-Free Oral Concentrate (methadone hydrochloride oral concentrate USP) dye-free, sugar-free, unflavored CII Rx only FOR ORAL USE ONLY Deaths have been reported during initiation of methadone treatment for opioid dependence. In some cases, drug interactions with other drugs, both licit and illicit, have been suspected. However, in other cases, deaths appear to have occurred due to the respiratory or cardiac effects of methadone and too-rapid titration without appreciation for the accumulation of methadone over time. It is critical to understand the pharmacokinetics of methadone and to exercise vigilance during treatment initiation and dose titration (see DOSAGE AND ADMINISTRATION). Patients must also be strongly cautioned against self- medicating with CNS depressants during initiation of methadone treatment. Respiratory depression is the chief hazard associated with methadone hydrochloride administration. Methadone's peak respiratory depressant effects typically occur later, and persist longer than its peak analgesic effects, particularly in the early dosing period. These characteristics can contribute to cases of iatrogenic overdose, particularly during treatment initiation and dose titration. Cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, NDA
    [Show full text]